Biorepository
The UK CF Infection Biorepository (UKCFIB) was launched in Autumn 2021 to address a key challenge in CF antimicrobial discovery and development: the difficulty researchers face to access all the sample types they need for preclinical testing.

About the UK CF Infection Biorepository
Our vision is to build and strengthen access to high quality clinically relevant samples, data and expertise to enable researchers from academia and industry to identify and translate discoveries into new treatments for infections in people with cystic fibrosis, faster.
The biorepository runs as a coordinated national network of UK labs, each with existing collections and capability:

Accessing Samples and Capability from the UK CF Infection Biorepository
The biorepository supplies samples and engages in collaborative projects with academic and industry researchers in the UK and abroad.
Please complete the enquiry form to submit a request. If we think we are able to fulfill your sample request, we will set up a call with you to discuss your needs in more detail. We will then link you up with one or more UK centres that can fulfill your request.
All access requests are centrally managed by Medicines Discovery Catapult (MDC), which coordinates the UK network of participating laboratories. Requests for samples, data and capability are reviewed, approved and fulfilled by the relevant laboratory in the network with terms dependent upon the nature of the request. Please also see FAQs.
The Biorepository is generously supported by funding from the Cystic Fibrosis Trust, Antabio and the Cystic Fibrosis Foundation.